Cosmo Pharmaceuticals NV
SIX:COPN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
IE |
|
M
|
Myriad Genetics Inc
XHAM:MYD
|
US |
|
S
|
Shin-Etsu Chemical Co Ltd
XMUN:SEH
|
JP |
|
Fox Factory Holding Corp
NASDAQ:FOXF
|
US |
|
D
|
Danieli & C Officine Meccaniche SpA
MIL:DAN
|
IT |
|
Bavarian Nordic A/S
F:BV3A
|
DK |
|
B
|
Beiersdorf AG
F:BEIA
|
DE |
|
A
|
Arribatec Group ASA
OSE:ARR
|
NO |
|
A
|
Avacta Group PLC
F:RTQ1
|
UK |
|
K
|
KeyMed Biosciences Inc
F:64Z
|
CN |
Wall St Price Targets
COPN Price Targets Summary
Cosmo Pharmaceuticals NV
According to Wall Street analysts, the average 1-year price target for COPN is 131.38 CHF with a low forecast of 102.01 CHF and a high forecast of 168 CHF.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is COPN's stock price target?
Price Target
131.38
CHF
According to Wall Street analysts, the average 1-year price target for COPN is 131.38 CHF with a low forecast of 102.01 CHF and a high forecast of 168 CHF.
What is the Revenue forecast for Cosmo Pharmaceuticals NV?
Projected CAGR
38%
Over the last 14 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 8 years is 38%.
What is the Gross Profit forecast for Cosmo Pharmaceuticals NV?
Projected CAGR
44%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 8 years is 44%.
